BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

The fluorescent labeling compound—dubbed "Sialyl Lewis Yellow"—was developed by an international team led from the Pohang University of Science and Technology in South Korea. It works by binding to ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

As new '-omics' fields are explored to assess molecular markers for cancer, bias will increasingly be recognized as the most important 'threat to validity' that must be addressed in the design ...

Landmark study uncovers role of tumour microenvironment in nasopharyngeal carcinoma progression which supports personalised treatment Molecular profiling of over 1,000 nasopharyngeal cancer (NPC) ...

Beyond cervical cancer, the relationships between tumor metabolic parameters and peripheral inflammatory marker have been also studied in other different cancer types, such as colorectal (8), small ...

More information: Eugenia Li Ling Yeo et al, Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes, Cell Reports Medicine (2025).

Introduction The last three decades have seen considerable progress in the management of patients diagnosed with nasopharyngeal cancer (NPC). While highly conformal radiotherapy (RT) remains the ...

Patients with residual nasopharyngeal carcinoma after receiving standard-of-care treatment have poor prognoses. In this trial, we aimed to assess the efficacy and safety of capecitabine maintenance ...

BAMF Health in Grand Rapids has launched a study to identify markers for targeted breast cancer therapies using PET scans.